13,126 Shares in United Therapeutics Co. (NASDAQ:UTHR) Bought by Massar Capital Management LP

Massar Capital Management LP acquired a new position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 13,126 shares of the biotechnology company's stock, valued at approximately $4,631,000. United Therapeutics makes up about 5.3% of Massar Capital Management LP's investment portfolio, making the stock its 4th largest position.

Other large investors have also added to or reduced their stakes in the company. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the 4th quarter valued at about $25,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics in the 4th quarter worth $67,000. MassMutual Private Wealth & Trust FSB raised its position in shares of United Therapeutics by 31.9% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company's stock valued at $85,000 after buying an additional 58 shares in the last quarter. Natixis purchased a new position in United Therapeutics in the fourth quarter worth $85,000. Finally, Anchor Investment Management LLC raised its position in United Therapeutics by 12.0% during the fourth quarter. Anchor Investment Management LLC now owns 280 shares of the biotechnology company's stock valued at $99,000 after purchasing an additional 30 shares in the last quarter. Institutional investors own 94.08% of the company's stock.

United Therapeutics Stock Down 1.7 %

Shares of UTHR traded down $5.04 during trading hours on Friday, reaching $291.38. 311,498 shares of the company traded hands, compared to its average volume of 447,735. The company has a market capitalization of $13.09 billion, a price-to-earnings ratio of 12.80, a price-to-earnings-growth ratio of 0.97 and a beta of 0.63. The company's fifty day moving average price is $310.30 and its two-hundred day moving average price is $346.99. United Therapeutics Co. has a 12 month low of $233.31 and a 12 month high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. During the same period in the previous year, the business earned $4.36 EPS. On average, analysts expect that United Therapeutics Co. will post 24.48 EPS for the current year.

Insider Activity

In other news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $353.64, for a total transaction of $3,536,400.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $911,330.28. This represents a 79.51 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul A. Mahon sold 11,000 shares of the company's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the sale, the executive vice president now directly owns 36,781 shares in the company, valued at approximately $11,261,606.58. The trade was a 23.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 84,500 shares of company stock valued at $28,179,150 in the last ninety days. Corporate insiders own 11.90% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of United Therapeutics from $357.00 to $355.00 and set an "overweight" rating on the stock in a research note on Monday. StockNews.com raised United Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and issued a $425.00 price objective on shares of United Therapeutics in a research report on Thursday, February 27th. Bank of America upgraded shares of United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a report on Monday. Finally, Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 price target (down from $395.00) on shares of United Therapeutics in a report on Friday. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat, United Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $390.17.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.